Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

HDAC inhibition potentiates immunotherapy in triple negative breast cancer
Manuela Terranova-Barberio, Scott Thomas, Niwa Ali, et al.
Oncotarget (2017) Vol. 8, Iss. 69, pp. 114156-114172
Open Access | Times Cited: 153

Showing 1-25 of 153 citing articles:

Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Karthik Dhatchinamoorthy, Jeff D. Colbert, Kenneth L. Rock
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 698
Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
Daphné Morel, Daniel Jeffery, Sandrine Aspeslagh, et al.
Nature Reviews Clinical Oncology (2019) Vol. 17, Iss. 2, pp. 91-107
Open Access | Times Cited: 388
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Hao Zhang, Ziyu Dai, Wantao Wu, et al.
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 357
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
Matthew D. Vesely, Tianxiang Zhang, Lieping Chen
Annual Review of Immunology (2022) Vol. 40, Iss. 1, pp. 45-74
Closed Access | Times Cited: 270
Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy
M. Janaki Ramaiah, Anjana Devi Tangutur, M. Rajasekhar Reddy
Life Sciences (2021) Vol. 277, pp. 119504-119504
Closed Access | Times Cited: 224
Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade
Qin Ye, Shauna N. Vasilatos, Lin Chen, et al.
Oncogene (2018) Vol. 38, Iss. 3, pp. 390-405
Open Access | Times Cited: 184
Cancer epigenetics in clinical practice
Verónica Dávalos, Manel Esteller
CA A Cancer Journal for Clinicians (2022) Vol. 73, Iss. 4, pp. 376-424
Open Access | Times Cited: 158
DNMT1: A key drug target in triple-negative breast cancer
Kah Keng Wong
Seminars in Cancer Biology (2020) Vol. 72, pp. 198-213
Closed Access | Times Cited: 145
Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
Zhengyi Wang, Xiaoying Wu
Cancer Medicine (2020) Vol. 9, Iss. 21, pp. 8086-8121
Open Access | Times Cited: 145
Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials
Lourdes Hontecillas‐Prieto, Rocío Flores-Campos, Andrew Silver, et al.
Frontiers in Genetics (2020) Vol. 11
Open Access | Times Cited: 142
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
Manuela Terranova-Barberio, Nela Pawłowska, Mallika Dhawan, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 141
Deregulation of HLA-I in cancer and its central importance for immunotherapy
Ahmet Hazini, Kerry Fisher, Leonard W. Seymour
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 8, pp. e002899-e002899
Open Access | Times Cited: 141
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives
Robert Jenke, Nina Reßing, Finn K. Hansen, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 634-634
Open Access | Times Cited: 137
Cancer immunotherapy: it’s time to better predict patients’ response
Charlotte Pilard, Marie Ancion, Philippe Delvenne, et al.
British Journal of Cancer (2021) Vol. 125, Iss. 7, pp. 927-938
Open Access | Times Cited: 127
Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy
Jing Liu, Zhihao Zhao, Nasha Qiu, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 124
The role of epigenetic modifications in drug resistance and treatment of breast cancer
Mohsen Karami Fath, Ali Azargoonjahromi, Arash Kiani, et al.
Cellular & Molecular Biology Letters (2022) Vol. 27, Iss. 1
Open Access | Times Cited: 88
An Update of Epigenetic Drugs for the Treatment of Cancers and Brain Diseases: A Comprehensive Review
Zahra Sahafnejad, Shahin Ramazi, Abdollah Allahverdi
Genes (2023) Vol. 14, Iss. 4, pp. 873-873
Open Access | Times Cited: 44
Epigenetic Regulation in Breast Cancer: Insights on Epidrugs
Ayoung Kim, Kyumin Mo, Hyeonseok Kwon, et al.
Epigenomes (2023) Vol. 7, Iss. 1, pp. 6-6
Open Access | Times Cited: 43
Circulating tumor cells: from new biological insights to clinical practice
Xuyu Gu, Shiyou Wei, Xin Lv
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 32
Epigenetic regulation in cancer
Minzhi Gu, Bo Ren, Yuan Fang, et al.
MedComm (2024) Vol. 5, Iss. 2
Open Access | Times Cited: 18
DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer
Varun Sasidharan Nair, Haytham El Salhat, Rowaida Z. Taha, et al.
Clinical Epigenetics (2018) Vol. 10, Iss. 1
Open Access | Times Cited: 130
Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)
Chunlong Zhao, Hang Dong, Qifu Xu, et al.
Expert Opinion on Therapeutic Patents (2020) Vol. 30, Iss. 4, pp. 263-274
Closed Access | Times Cited: 112
Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
Debarati Banik, Sara Moufarrij, Alejandro Villagra
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 9, pp. 2241-2241
Open Access | Times Cited: 109
RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade
Shanthi Ganesh, Xue Shui, Kevin P. Craig, et al.
Molecular Therapy (2018) Vol. 26, Iss. 11, pp. 2567-2579
Open Access | Times Cited: 90
Novel Approaches to Epigenetic Therapies: From Drug Combinations to Epigenetic Editing
Aleksandra Majchrzak‐Celińska, Anna Warych, Mikołaj Szoszkiewicz
Genes (2021) Vol. 12, Iss. 2, pp. 208-208
Open Access | Times Cited: 88
Page 1 - Next Page

Scroll to top